Phase 2 N=40 Safety, Tolerability, and Treatment Effect of Belnacasan in Patients With COVID-19
COVID-19
Primary: Safety and Tolerability of Belnacasan — 11; 10; 0; 0 Number of AEs and SAEs
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=34 Sunitinib or Cediranib for Alveolar Soft Part Sarcoma
Sarcoma, Alveolar Soft Part
Primary: Part I: Objective Response Rate (ORR) of Single-agent Cediranib in Participants With Advanced Alveolar Soft Part Sarcoma (ASPS) — 0; 0; 0; 1 Participants
Phase 2 N=15 ERG/5-HTP in Fragile X Syndrome (FXS)
Fragile X Syndrome
Primary: Safety and Tolerability - Number of Treatment-Emergent Adverse Events — 2; 1; 1; 3 Number of Adverse Events
Phase 2 N=17 1630GCC: Zydelig Maintenance in B-Cell Non-Hodgkin's Lymphoma After Autologous Stem Cell Transplantation
Non Hodgkin Lymphoma · Follicular Lymphoma · Indolent Lymphoma
Primary: Discontinuation Rate Due to Zydelig-related Adverse Events at 1 Year — 5 Participants
Phase 2 N=17 MT2015-20: Biochemical Correction of Severe EB by Allo HSCT and Serial Donor MSCs
Epidermolysis Bullosa
Primary: Event-free Survival — 4; 2; 1 Count of Participants
Phase 2 N=11 Remotely Supervised Transcranial Direct Current Stimulation (tDCS) for Primary Progressive Aphasia (PPA)
Primary Progressive Aphasia
Primary: Percentage of Participants Who Complete 16 Out of 20 Study Visits — 100 percentage of participants
Phase 2 N=26 A Trial to Evaluate the Male Reproductive Safety of Pretomanid in Adult Male Participants With Drug Resistant Pulmonary Tuberculosis
Tuberculosis, Pulmonary · Tuberculosis, Multidrug-Resistant · Tuberculosis, MDR
Primary: Change Form Baseline Total Sperm Count — 20 10^6 sperm cells/ejaculate
Phase 2 N=20 WT1 Vaccine Treatment of Patients With Multiple Myeloma After Autologous Stem Cell Transplantation
Multiple Myeloma
Primary: WT1 T-cell Immune Response (IR) 12-14 Weeks After First GPS Administration (6 x Administrations) — 9 Participants
Phase 2 N=154 Exploratory Clinical Study of MT-2301
Haemophilus Influenza Type b
Primary: Antibody Prevalence Rate Against Anti-PRP With 1 μg/mL or Higher, Defined as the Percentage of Participants With the Antibody Against Anti-PRP — 100.0; 96.2; 94.0…
Phase 2 N=52 Safety and Efficacy Study Using Gene Therapy for Critical Limb Ischemia
Critical Limb Ischemia
Primary: Number of Participants With Treatment-emergent Adverse Events Following Intramuscular Administration of 8 and 16 mg Engensis (VM202) or Placebo in Subjects With Critical…
Phase 2 N=156 QUILT-2.015: A Study of AMG 479 With Exemestane or Fulvestrant in Postmenopausal Women With Hormone Receptor Positive Locally Advanced or Metastatic Breast Cancer
Breast Cancer · Breast Tumors · Metastatic Cancer
Primary: Progression Free Survival (PFS) — 3.9; 5.7 Months
Phase 2 N=23 Propranolol for Sleep Apnea Therapy
Obstructive Sleep Apnea
Primary: Nocturnal Heart Rate (Beats/Min, BPM) — 64.1; 60.2 BPM
Phase 2 N=91 A Study to Evaluate the Safety and Efficacy of AVTX-002 for the Treatment of Poorly Controlled Non-Eosinophilic Asthma.
Non-Eosinophilic Asthma
Primary: The Ability of AVTX-002 to Improve Asthma Control in Subjects With Poorly Controlled Non-eosinophilic Asthma (NEA) Based on the Percentage of Patients Who Experience…
Phase 2 N=68 Evaluation of the Safety and Effectiveness of Aceclidine/Brimonidine (LNZ101) and Aceclidine (LNZ100) in the Treatment of Presbyopia
Presbyopia · Refractive Errors · Eye Diseases
Primary: Percentage of Participants With a ≥ 3-line Improvement in Near Vision and no Loss ≥ 5 Letters Distance Vision — 56.0; 71.4; 5.9 percentage of participants — p=<0.0001
Phase 2 N=59 The Effectiveness of CD388 to Prevent Flu in an Influenza Challenge Model in Healthy Adults
Influenza
Primary: Mean Area Under the Viral Load-Time Curve (VL-AUC) After Influenza Viral Challenge — 16.09; 10.70 log[10] copies/milliliter (mL)*hour — p=0.0390